Clinical Trial Update: Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating temozolomide as second-line treatment for neuroendocrine carcinomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Neuroendocrine Carcinomas | Phase 2 | Status: COMPLETED